Activation of ERBB4 in Glioblastoma Can Contribute to Increased Tumorigenicity and Influence Therapeutic Response

Activation of ERBB4 in Glioblastoma Can Contribute to Increased Tumorigenicity and Influence Therapeutic Response

Glioblastoma (GBM) is often resistant to conventional and targeted therapeutics. ErbB2 Receptor Tyrosine Kinase 4 (ERBB4) is expressed throughout normal brain and is an oncogene in several pediatric brain cancers; therefore, we investigated ERBB4 as a prognostic marker and therapeutic target in GBM....

Full description

Bibliographic Details
Main Authors: Jacqueline F. Donoghue, Lauren T. Kerr, Naomi W. Alexander, Sameer A. Greenall, Anthony B. Longano, Nicholas G. Gottardo, Rong Wang, Viviane Tabar, Timothy E. Adams, Paul S. Mischel, Terrance G. Johns
Format: Article
Language:English
Published: MDPI AG 2018-07-01
Series:Cancers
Subjects:
GBM
EGFR
ERBB4
prognosis
therapy
Online Access:http://www.mdpi.com/2072-6694/10/8/243

Internet

http://www.mdpi.com/2072-6694/10/8/243

Similar Items